Update
$Ocugen(OCGN.US$ Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
2 MINUTES AGO, 7:02 AM EDT
VIA GLOBENEWSWIRE
• Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial
• DSMB Approval to Proceed with Medium Dose Cohort Dosing
2 MINUTES AGO, 7:02 AM EDT
VIA GLOBENEWSWIRE
• Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial
• DSMB Approval to Proceed with Medium Dose Cohort Dosing
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
